High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group
Joint Authors
Gaspar, Nathalie
Segura-Ferlay, Céline
Tabone, Marie-Dominique
Pacquement, Helene
Lervat, Cyril
Gentet, Jean-Claude
Schmitt, Claudine
Brugières, Laurence
Marec-Bérard, Perrine
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2013), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-02-04
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Introduction.
Osteosarcoma relapse has a poor prognosis, with less than 25% survival at 5 years.
We describe the experience of the French Society of Paediatric Oncology (SFCE) with high dose (HD) thiotepa and autologous stem cell transplantation (ASCT) in 45 children with relapsed osteosarcoma.
Patients and Methods.
Between 1992 and 2004, 53 patients received HD thiotepa (900 mg/m2) followed by ASCT in 6 centres.
Eight patients were excluded from analysis, and we retrospectively reviewed the clinical radiological and anatomopathological patterns of the 45 remaining patients.
Results.
Sixteen girls and 29 boys (median age, 15.9 years) received HD thiotepa after initial progression of metastatic disease (2), first relapse (26), and second or third relapse (17).
We report 12 radiological partial responses and 9 of 31 histological complete responses.
Thirty-two patients experienced further relapses, and 13 continued in complete remission after surgical resection of the residual disease.
Three-year overall survival was 40%, and 3-year progression-free survival was 24%.
Delay of relapse (+/− 2 years from diagnosis) was a prognostic factor (P=0.011).
No acute toxic serious adverse event occurred.
Conclusion.
The use of HD thiotepa and ASCT is feasible in patients with relapsed osteosarcoma.
A randomized study for recurrent osteosarcoma between standard salvage chemotherapy and high dose thiotepa with stem cell rescue is ongoing.
American Psychological Association (APA)
Marec-Bérard, Perrine& Segura-Ferlay, Céline& Tabone, Marie-Dominique& Pacquement, Helene& Lervat, Cyril& Gentet, Jean-Claude…[et al.]. 2014. High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group. Complexity،Vol. 2014, no. 2014, pp.1-7.
https://search.emarefa.net/detail/BIM-1047449
Modern Language Association (MLA)
Marec-Bérard, Perrine…[et al.]. High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group. Complexity Vol. 2014, no. 2014 (2013), pp.1-7.
https://search.emarefa.net/detail/BIM-1047449
American Medical Association (AMA)
Marec-Bérard, Perrine& Segura-Ferlay, Céline& Tabone, Marie-Dominique& Pacquement, Helene& Lervat, Cyril& Gentet, Jean-Claude…[et al.]. High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group. Complexity. 2014. Vol. 2014, no. 2014, pp.1-7.
https://search.emarefa.net/detail/BIM-1047449
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1047449